TRIDENT: Relacorilant in Combination with Chemotherapy for the First Line Treatment of Pancreatic Cancer

Condition: Pancreatic Cancer

Sponsor: Corcept Therapeutics

Full Title
Protocol CORT125134-558: A Phase 2, Single-Arm Trial of Relacorilant in Combination with Nab-Paclitaxel and Gemcitabine in Patients with Previously Untreated Metastatic Pancreatic Adenocarcinoma

Study Treatment
Relacorilant, an orally administered glucocorticoid receptor antagonist given in combination with Gemcitabine and nab-Paclitaxel 

Eligibility/Info
Eligible patients must have a metastatic pancreatic ductal adenocarcinoma that has not been treated in the advanced/metastatic setting. 

Contact
For more information about this or any other study, please contact the NYCBS Research Department:
Email: ResearchRecruitment@nycancer.com
Telephone: 631-675-5075
HALO Messaging App: "Research Team"

Locations
Babylon Medical Oncology
Central Park Medical Oncology
Eastchester Cancer Center
Lake Success Medical Oncology
Nostrand Medical Oncology
Patchogue Medical Oncology
Port Jefferson Medical Oncology
Port Jefferson Station Medical Oncology
Riverhead Medical Oncology

Go To Trial Homepage